Table 3.
Multivariate logistic regression analysis
| OR (95% CI) | p value | |
|---|---|---|
| Paraesthesia 3 years after start of CTx (n = 312a) | ||
| Age (years, +10) b | 1.34 (1.07–1.68) | 0.0105 |
| CCI (+1) | 1.06 (0.72–1.61) | 0.7589 |
| Diabetes (yes vs. no) | 1.71 (0.50–6.60) | 0.4089 |
| Paraesthesia 4 weeks after start of CTx (yes vs. no) | 3.72 (2.15–6.67) | <0.0001 |
| Taxane-based regimen (yes vs. no) | 1.65 (1.01–2.69) | 0.0447 |
| Endocrine therapy(yes vs. no) | 1.21 (0.73–2.01) | 0.4639 |
| Post-surgical symptoms 3 years after start of CTx (n = 269c) | ||
| Age (years, +10)b | 0.89 (0.69–1.14) | 0.3692 |
| CCI (+1) | 1.01 (0.70-1.52) | 0.9421 |
| Tumour size(Tis,T1,T2 vs. T3,T4,TX) | 2.43 (0.72–8.55) | 0.1544 |
| Number of removed lymph nodes (+1) | 1.01 (0.98–1.04) | 0.6153 |
| Breast-conserving surgery (yes vs. no)d | 0.76 (0.34–1.65) | 0.4874 |
| Radiotherapy (lymph node/thorax vs. none) | 2.00 (0.75–5.53) | 0.1709 |
| Radiotherapy (mamma vs. none) | 2.10 (0.96–4.65) | 0.0648 |
| Pain at the operated site 4 weeks after start of CTx (yes vs. no) | 4.52 (2.62–7.95) | <0.0001 |
| Endocrine therapy(yes vs. no) | 0.66 (0.35–1.21) | 0.1883 |
Bold writing p < 0.05
CCI Charlson comorbidity index, CI confidence interval, CTx chemotherapy, OR odds ratio
aOf 453 patients, 141 were excluded: 19 because of at least one parameter missing and 122 had not sent back the 3-year questionnaire; 176 of 312 patients reported symptoms of paraesthesia 3 years after start of chemotherapy
bAt diagnosis
cOf 453 patients, 184 were excluded: 62 because of at least one parameter missing and 122 had not sent back the 3-year questionnaire; 178 of 269 patients reported post-surgical symptoms 3 years after start of chemotherapy
dOf the primary tumour